UPDATE : US FDA Warning Letter related to excipients produced by DuPont at 1301 Ogletown Rd, Newark, DE 19711, United States.
Enforcement Report - Week of March 8, 2023
DuPont Nutrition USA Inc. Receives FDA Warning Letter
Enforcement Report - Week of September 29, 2021
Enforcement Report - Week of August 25, 2021
IFF (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF) and DuPont (NYSE: DD) announced that, during a special meeting held earlier today, IFF shareholders voted to approve the issuance of shares of IFF common stock in connection with the previously announced proposed merger of IFF and DuPont’s Nutrition & Biosciences (N&B) business pursuant to a Reverse Morris Trust transaction. Based on the preliminary count of proxies returned prior to its special meeting, and with more than 99 percent of the votes cast in favor, IFF shareholders overwhelmingly approved the issuance of shares pursuant to the merger agreement, through which IFF and N&B will combine to create a global leader in high-value ingredients and solutions for global food, beverage, home and personal care and health and wellness markets. The final voting results will be publicly filed with the Securities and Exchange Commission on a Form 8-K within four business days.
DuPont Nutrition & Biosciences (DuPont) today announced a research collaboration in microbiome science with the Center for Advanced Biotechnology and Medicine (CABM) at Rutgers University in New Jersey.
DuPont Nutrition & Biosciences (booth 966) will present 12 poster presentations AAPS PharmSci 360 addressing efficient and cost- saving solutions for taste-masking, abuse deterence, biologic stabilization and more.
DuPont Nutrition & Biosciences, a business unit of DuPont Specialty Products, is going to showcase a comprehensive portfolio of pharmaceutical solutions at CPhI China 2019 in Shanghai International Expo Center from June 18 to June 20. The innovative range will address some of the most crucial drug formulation challenges currently faced by the industry.
There are several recent announcements of German companies opening laboratories in the U.S. It is probably not related to the recent news that the U.S. Justice Department gave Germany-based Bayer and U.S.-based Monsanto the go-ahead for their merger. Due to anti-trust issues, Monsanto has to sell about $9 billion in assets, and European regulators also required the sale of $2.54 billion in assets, which are being sold to BASF. The deal is expected to close by the end of June. After the various divestment, the combined agricultural supplies company will have sales of about 20 billion euros.